Abstract
Despite the increasing need for antibiotics to fight infectious diseases, fewer new antibiotics are available on the market. Unfortunately, developing a new class of antibiotics is associated with high commercial risk. Therefore, modification or combination of existing antibiotics to improve their efficacy is a promising strategy. Herein, we conjugated the antibiotic, levofloxacin, with two peptides, i.e. an antimicrobial peptide indolicidin and a cell penetrating peptide (TAT). Glycolic acid and glycine linkers were used between levofloxacin and peptides. We developed an optimized condition for coupling of levofloxacin via its carboxylic group to glycolic acid using solid phase peptide synthesis (SPPS). Antibacterial and haemolytic assays were carried out on the conjugates and only the levofloxacin-indolicidin conjugate demonstrated moderate antibacterial activity. Interestingly, physical mixture of levofloxacin and indolicidin showed improvement in the activity against Gram-positive bacteria.
Keywords: Antibiotic, levofloxacin, indolicidin, TAT peptide, conjugation.
Current Drug Delivery
Title:Levofloxacin and Indolicidin for Combination Antimicrobial Therapy
Volume: 12 Issue: 1
Author(s): Khairunnisa Abdul Ghaffar, Waleed M. Hussein, Zeinab G. Khalil, Robert J. Capon, Mariusz Skwarczynski and Istvan Toth
Affiliation:
Keywords: Antibiotic, levofloxacin, indolicidin, TAT peptide, conjugation.
Abstract: Despite the increasing need for antibiotics to fight infectious diseases, fewer new antibiotics are available on the market. Unfortunately, developing a new class of antibiotics is associated with high commercial risk. Therefore, modification or combination of existing antibiotics to improve their efficacy is a promising strategy. Herein, we conjugated the antibiotic, levofloxacin, with two peptides, i.e. an antimicrobial peptide indolicidin and a cell penetrating peptide (TAT). Glycolic acid and glycine linkers were used between levofloxacin and peptides. We developed an optimized condition for coupling of levofloxacin via its carboxylic group to glycolic acid using solid phase peptide synthesis (SPPS). Antibacterial and haemolytic assays were carried out on the conjugates and only the levofloxacin-indolicidin conjugate demonstrated moderate antibacterial activity. Interestingly, physical mixture of levofloxacin and indolicidin showed improvement in the activity against Gram-positive bacteria.
Export Options
About this article
Cite this article as:
Ghaffar Abdul Khairunnisa, Hussein M. Waleed, Khalil G. Zeinab, Capon J. Robert, Skwarczynski Mariusz and Toth Istvan, Levofloxacin and Indolicidin for Combination Antimicrobial Therapy, Current Drug Delivery 2015; 12 (1) . https://dx.doi.org/10.2174/1567201811666140910094050
DOI https://dx.doi.org/10.2174/1567201811666140910094050 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
Current Medicinal Chemistry Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Getting in Sync: A New Ready-to-use Biofield Resonance Device (Vita Chip) Reduces Chronic Pain and Increases Wellbeing
Neuroscience and Biomedical Engineering (Discontinued) NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Current Pharmaceutical Design Base Excision Repair: Contribution to Tumorigenesis and Target in Anticancer Treatment Paradigms
Current Medicinal Chemistry Modulation of the Cell Cycle and Induction of Apoptosis in Human Cancer Cells by Synthetic Bile Acids
Current Cancer Drug Targets In Silico Prediction and Validation of Oxygen-Regulated Protein N-myc Downstream Regulated Gene 3 and Virtual Screening of Competitive Inhibitors of L-Lactate as Therapeutics
Letters in Drug Design & Discovery MUC Glycoproteins: Potential Biomarkers and Molecular Targets for Cancer Therapy
Current Cancer Drug Targets Allelic Variations in CYP2D6 Gene and Susceptibility to Cervical Cancer
Drug Metabolism Letters Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design miR-15b Suppression of Bcl-2 Contributes to Cerebral Ischemic Injury and is Reversed by Sevoflurane Preconditioning
CNS & Neurological Disorders - Drug Targets Melanoma Immunotherapy: Past, Present, and Future
Current Pharmaceutical Design Synthetic and Natural Coumarins as Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Hypermethylation of Single CpG Dinucleotides at the Promoter of CXCL13 Gene Promoting Cell Migration in Cervical Cancer
Current Cancer Drug Targets Synthesis and Biological Evaluation of New Piperazine Substituted 3, 5-Diarylisoxazolines
Current Organic Synthesis Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Fgf10: A Paracrine-Signaling Molecule in Development, Disease, and Regenerative Medicine
Current Molecular Medicine P-glycoprotein and Vacuolar ATPase Synergistically Confer Anthracycline Resistance to Fission Yeast and Human Cells
Current Medicinal Chemistry Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets Stem Cells as a Potential Therapeutic Option for Treating Neurodegenerative Diseases
Current Stem Cell Research & Therapy